Bio­gen qui­et­ly whisks away its $544M au­toim­mune ri­val to Cel­gene

Bio­gen is sup­posed to be hunt­ing up new deals to fat­ten its late-stage pipeline. In­stead, the com­pa­ny used its quar­ter­ly num­bers re­view to­day to whisk one of its pro­grams out the back door with as lit­tle com­ment as pos­si­ble.

At the end of a ros­ter of pos­i­tive events in Q3, the big biotech not­ed: Bio­gen has dis­con­tin­ued de­vel­op­ment of amise­limod (MT-1303), which tar­gets the sphin­go­sine 1-phos­phate (S1P) re­cep­tor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER